caa a22 4500 475817915 CHVBK 20180406123814.0 cr unu---uuuuu 170329e20000101xx s 000 0 eng 10.1007/s002280050007 doi (NATIONALLICENCE)springer-10.1007/s002280050007 Site of nicotine absorption from a vapour inhaler - comparison with cigarette smoking [Elektronische Daten] [E. Lunell, L. Molander, K. Ekberg, J. Wahren] Objective: The aim of the study was to assess the site of nicotine absorption during and after use of a nicotine-vapour inhaler compared with that after cigarette smoking. Methods: Using a catheterisation technique, the nicotine plasma concentration-time profiles in arterial and jugular venous blood after using a nicotine inhaler were compared with those achieved after cigarette smoking a in seven healthy habitual smokers. Results: After use of the inhaler, arterial nicotine concentrations rose slowly to a maximum level of 5.9 ± 1.5 ng/ml at a mean time to reach peak concentration (t max) of 9.0 ± 1.1 min, whereas jugular venous nicotine levels peaked at 25.4 ± 5.4 ng/ml at 6.7 ± 0.3 min. The concentration-time curves indicate that the absorption occurs mainly via the mucosa of the oral cavity and the pharynx, and that there is minimal absorption via the lungs. In contrast, after smoking a cigarette, arterial nicotine plasma concentrations rose quickly to a maximum level of 49.2 ± 9.7 ng/ml after 4.0 ± 0.6 min, while the maximum concentration of nicotine in the jugular vein was 22.4 ± 3.9 ng/ml after 6.4 ± 0.4 min, indicating primarily pulmonary absorption of nicotine. Conclusion: Nicotine absorption after use of the vapour inhaler occurs primarily via the mucosa of the oral cavity; the absorption occurs slowly and the arterial nicotine concentration spike, typical of cigarette smoking, is avoided. Thus, the likelihood for abuse of the nicotine inhaler is probably small. Springer-Verlag Berlin Heidelberg, 2000 Key words Artery nationallicence Jugular vein nationallicence Arterio-venous concentration difference nationallicence Lunell E. Department of Clinical Pharmacology, University Hospital, Lund, Sweden, SE aut Molander L. Department of Clinical Pharmacology, Pharmacia and Upjohn, Karl XI gata 4, S-22220 Lund, Sweden e-mail: lars.molander@eu.pnu.com Tel.: +46-46-190606; Fax: +46-46-142917, SE aut Ekberg K. Department of Clinical Physiology, Karolinska Hospital, Stockholm, Sweden, SE aut Wahren J. Department of Clinical Physiology, Karolinska Hospital, Stockholm, Sweden, SE aut https://doi.org/10.1007/s002280050007 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050007 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lunell E. Department of Clinical Pharmacology, University Hospital, Lund, Sweden, SE aut NATIONALLICENCE 700 1- Molander L. Department of Clinical Pharmacology, Pharmacia and Upjohn, Karl XI gata 4, S-22220 Lund, Sweden e-mail: lars.molander@eu.pnu.com Tel.: +46-46-190606; Fax: +46-46-142917, SE aut NATIONALLICENCE 700 1- Ekberg K. Department of Clinical Physiology, Karolinska Hospital, Stockholm, Sweden, SE aut NATIONALLICENCE 700 1- Wahren J. Department of Clinical Physiology, Karolinska Hospital, Stockholm, Sweden, SE aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer